Coenzyme Q10 (Ubiquinol)New

Reviewed Sep 11, 2026

Coenzyme Q10 (CoQ10) is a lipid-soluble electron carrier in the mitochondrial respiratory chain and a membrane antioxidant; ubiquinol is its reduced, more readily absorbed form. Endogenous levels decline with age and are lowered further by statins, which block the shared mevalonate pathway. The clearest clinical signal is in chronic heart failure. A 2024 meta-analysis of 33 randomized controlled trials (BMC Cardiovascular Disorders) found that adding CoQ10 to standard therapy reduced all-cause mortality by about 36% (RR 0.64, 95% CI 0.48-0.85) and heart-failure hospitalization by about 50% (RR 0.50, 95% CI 0.37-0.67), while improving left-ventricular ejection fraction, 6-minute walk distance and lowering BNP and NYHA class - without major adverse effects. A separate 2024 meta-analysis focused on ubiquinol (16 studies, Future Cardiology) similarly reported roughly a 40% reduction in heart-failure mortality and better exercise capacity, though its effect on ejection fraction was not statistically significant. These findings echo an earlier 14-trial analysis (2,149 patients) that reported lower mortality (RR 0.69, 95% CI 0.50-0.95). Importantly, the mortality benefit seen in heart-failure trials does not clearly extend to the general population: a 2025 prospective NHANES cohort found that CoQ10 supplement use among US adults was not associated with lower all-cause (HR 1.00) or cardiovascular (HR 1.30) mortality. CoQ10 is a dietary supplement, not a drug, and is not intended to diagnose, treat, cure, or prevent any disease. Discuss use with your physician, especially if you take warfarin or other blood thinners.